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Editorial
The Heat shock proteins (HSPs) are molecular chaperons which 
regulates protein homeostasis. Any changes in this process 
can cause different diseases like neurodegenerative diseases, 
and cancer. The widely studied and used critical chaperons are 
Hsp 70 and Hsp 90 [1]. The heat shock factor-1 (HSF-1) is a 
transcriptional activator for Hsp70 chaperon  protein. In normal 
condition, HSF-1 maintains its inactive (monomeric) form by 
binding to Hsp90 protein. But in dysregulated intracellular 
homeostatic conditions HSF-1 separates from Hsp90 and transfers 
for upregulation of Hsp genes. The HSF-1 has ability to trigger 
the Hsp70 expression. Currently, Celastrol and Carbenoxolone 
drugs are available as a HSF-1 modulator. The pharmacological 
status of these drugs includes short-term clinical trials for 
rheumatoid arthritis and phase II clinical trials for psoriasis. 
But it has limitations like strong human toxicity. The Hsp90 
inhibitors have ability to inhibit the interaction between Hsp90 
and HSF-1, which is important for Hsp70 expression and activity. 
Commonly used Hsp90 inhibitors are Geldanamycin, 17-AAG 
(17-N-allylamino-17-demethoxygeldanamycin), 17- DMAG 
(17-Dimethylaminoethylamino-17-demethoxygeldanamycin), 
SNX-2112 used in clinical trials for the cancer but discontinued 
due to its toxic effect and poor blood brain barrier penetration. 
The intracellular protein homeostasis is maintained by chaperon 
protin regulation. The Hsp110, Hsp 40, NEF (BAG) and TPR 
(Hip) co-chaperons has critical role of ATP hydrolysis and client 
selection for Hsp70 (14). In further processes, Hsp40 (NEF)/
Hip (TPR) instructs Hsp70 for client stability on the other hand 
BAG (NEF)/ HSP110 are the destabilizes the interaction. This 
data directly suggest that the co-chaperons has major role in 
Hsp70 function. The important co-chaperons involved in this 
process are J proteins, tetratricopeptide repeat (TPR) domain, 
nucleotide exchange factors (NEF) [1]. Previous studies has 
discussed about the Hsp70 structure which contain SBD and 
NBD, the role of co- chaperons like J-domain on substrate and 
Hsp70 resulting in ATPhydrolysis at NBD allowing SBD to 
capture substrate of Hsp70, NEF role in making Hsp70 available 
for  substrate binding in next cycle endorsing polypeptide 
unfolding –refolding localized events, Efficiency of TPR for 
HSP 70 function (1,2, 11, 12). More attention is required for 
the study of these chaperon co-chaperon protein interactions 
(CCI) which can be a new therapeutic target in different disease 
models. The major function of this interaction (CCI) is protein 
folding, trafficking and degradation of protein aggregation. In 
neurodegeneration diseases HSP70 activation is important this 
can be achieve by using a molecules with promising protagonist 
of HSP 70 activation for protein disaggregation [2]. Currently 
many stimulators and inhibitors of chaperon available but 
they showed limitations for its use. HSP90 inhibitor treatment 
for longer period may cause degradation and disruption of 
its function [2]. On the opposite side HSP 70 overexpression 
triggers tumor progression and development by stabilizing 
oncogenic kinases. The HSP70 binds to a specific region 
on co-chaperon for its function and the discovery of small 
molecules with the ability to block or modulate this interaction 
in mutated or dysregulated Hsps can play major role in the 
treatment therapy for different diseases. The small molecules 
play role as an inhibitor for chaperon co-chaperon interaction 
(CCI) by targeting the binding site for Hsp70 on co-chaperon 
and to blocks its expression. These inhibitors provide the novel 
therapeutic approach in cancer [3]. Researchers should focus 
on the interactions between Hsp70 and its co-chaperones as a 
new therapeutic target. It is also important to study CCI in detail 
and the mechanism involved in action of activator/inhibitor on 
CCI. The treatment therapy with low toxicity CCI stimulating/ 
activating molecule of Hsp 90 can be the effective therapy in 
Cancer disease.
The difficulty in this approach is to target CCIs (Hsps and co-
chaperon). Development of Novel therapies is growing research 
topic in this area. The Hsps might be an attractive target for 
developing high number of CCI in guiding Hsps for the 
interaction.
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